Subsequent mechanistic investigations revealed that ivosidenib directly targets the m6A reader protein YTHDC2 in IDH1 wild-type cancer cells, thereby impairing homologous recombination (HR) repair capacity in these BRCA-competent malignancies. The gene discussed is IDH1; the disease is cancer.